CFTR and cystic fibrosis: The combination of the corrector elexacaftor (VX-445), tezacaftor (VX-661) and the potentiator ivacaftor (VX-770) was successfully approved for therapy of CF patients with at least one allele of the most common F508del-CFTR mutation [25].